Last reviewed · How we verify
Brimonidine tartrate ophthalmic solution 0.025%
Brimonidine tartrate ophthalmic solution 0.025% is a Small molecule drug developed by Bausch & Lomb Incorporated. It is currently FDA-approved. Also known as: Lumify™, Lumify.
At a glance
| Generic name | Brimonidine tartrate ophthalmic solution 0.025% |
|---|---|
| Also known as | Lumify™, Lumify |
| Sponsor | Bausch & Lomb Incorporated |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Upneeq vs. Lumify Ptosis (PHASE4)
- Evaluating Injection With the Use of Brimonidine Tartrate Ophthalmic 0.025% on Patients Using Netarsudil 0.02%/Latanoprost 0.005% to Treat Glaucoma (PHASE4)
- The Effect of Lumify™ on Ocular Redness, Intraocular Pressure, and Eyelid Position in Glaucoma Patients (PHASE4)
- Evaluation of the Safety and Pharmacokinetics of Brimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Combination Ophthalmic Solution (PHASE3)
- A Study Comparing the Efficacy and Safety of Brimonidine Tartrate Ophthalmic Solution 0.025% With Sodium Hyaluronate Relative to Lumify in Adult Subjects With Ocular Redness (PHASE3)
- Evaluation of Brimonidine Tartrate/Ketotifen Fumarate Combination in Adults With Seasonal Allergic Conjunctivitis (PHASE3)
- Brimonidine Eye Drops in the Prevention of Myopia Progression (PHASE2)
- Evaluation of Brimonidine Tartrate/Ketotifen Fumarate Combination for the Treatment of Allergic Conjunctivitis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Brimonidine tartrate ophthalmic solution 0.025% CI brief — competitive landscape report
- Brimonidine tartrate ophthalmic solution 0.025% updates RSS · CI watch RSS
- Bausch & Lomb Incorporated portfolio CI
Frequently asked questions about Brimonidine tartrate ophthalmic solution 0.025%
What is Brimonidine tartrate ophthalmic solution 0.025%?
Brimonidine tartrate ophthalmic solution 0.025% is a Small molecule drug developed by Bausch & Lomb Incorporated.
Who makes Brimonidine tartrate ophthalmic solution 0.025%?
Brimonidine tartrate ophthalmic solution 0.025% is developed and marketed by Bausch & Lomb Incorporated (see full Bausch & Lomb Incorporated pipeline at /company/bausch-lomb-incorporated).
Is Brimonidine tartrate ophthalmic solution 0.025% also known as anything else?
Brimonidine tartrate ophthalmic solution 0.025% is also known as Lumify™, Lumify.
What development phase is Brimonidine tartrate ophthalmic solution 0.025% in?
Brimonidine tartrate ophthalmic solution 0.025% is FDA-approved (marketed).
Related
- Manufacturer: Bausch & Lomb Incorporated — full pipeline
- Also known as: Lumify™, Lumify
- Compare: Brimonidine tartrate ophthalmic solution 0.025% vs similar drugs
- Pricing: Brimonidine tartrate ophthalmic solution 0.025% cost, discount & access